Figure 5.

OVX836 vaccine generates lung NP-specific CD8+ TRM cells. C57BL/6 mice (n = 9–10 in each group) were immunized twice 3 weeks apart, with 30 µg of NPm, NPwt, OVX836, or buffer (control) by the IM route. At D28, anti-CD45 Abs were administered by the IV route to label vascular cells. (A) Representative flow cytometry analysis of circulating (CD45+) and resident (CD45−) distribution in the lung after immunization. (B) Representative flow cytometry analysis of circulating and resident lung NP_366–374-specific CD8+ T-cells using H2-Db NP_366–374 pentamer staining. (C) Ratio resident/circulating of percent H-2Db NP_366–374 Pentamer + CD8+ T-cells of two independent experiments. (D) Representative overlay plots of flow cytometric analysis showing distribution of lung-resident H-2Db NP_366–374 Pentamer⁺CD8⁺CD45⁻ T-cell (red dots) TRM generated following vaccination among the CD69+CD103+ (black) population. (E) Graph representing percent resident H-2Db-NP_366–374 Pentamer+ among CD8+CD69+CD103+ cells in the lung after vaccination of two pooled independent experiments. Individual data and mean ± SEM are represented. Differences were assessed by one-way ANOVA followed by Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.